Inhibition of the LHb glutamatergic pathway ameliorates depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson's disease mouse model

Key Points

• Amelioration of depressive-like behaviors occurs with LHb glutamatergic pathway inhibition.
• Key improvement noted in 6-OHDA-induced Parkinson's disease models.
• Analysis of the glutamatergic pathway's role showcases potential therapeutic targets.
• Highlights the need for further exploration of PD-related depression treatments.

Abstract